Vasomune Therapeutics, Inc.
Vasomune Therapeutics is a private clinical-stage biopharmaceutical company focused on developing novel therapeutics for diseases associated with vascular dysfunction. Their lead drug candidate, AV-001, aims to enhance the body's ability to defend against illness by stabilizing the vascular endothelial response to disease, particularly in conditions like Acute Respiratory Distress Syndrome (ARDS).
Vasomune Therapeutics, Inc.
180 John Street, Suite 305, Toronto, ON M5T 1X5
What We Do
AV-001 is a first-in-class synthetic Angiopoietin 1 mimetic designed to activate the Tie2 receptor, promoting vascular stability and counteracting vascular inflammation. It is being developed for the treatment of pathogen-induced Acute Respiratory Distress Syndrome (ARDS) and other conditions associated with vascular dysfunction.
Regenerative Medicine
Digital Health Technologies
Vaccines
Battlefield Resuscitation
Infectious Diseases
Key People
President & COO
Vice-President, Research & Scientific Affairs
Vice-President, Finance
Vice-President, Operations & Planning
News & Updates
Vasomune Therapeutics has received Fast Track Designation from the US FDA for AV-001, a novel investigational medicine.
Vasomune Therapeutics has been selected to present its lead drug candidate AV-001 at the 2024 Respiratory Innovation Summit.
Vasomune and AnGes announced that AV-001 received a positive recommendation from the IDSMB for the Phase 2a study.